NIH

A novel immunotherapy combination induced remarkable regression of tumors in a mouse model of head and neck cancer. Read More

A PET probe that detects the amino acid glutamine predicts whether tumors respond to certain targeted therapies in preclinical animal models. Read More

New findings shed light on how enzymes that replicate DNA skip over mutations that might cause cancer and restart DNA synthesis further away. Read More

Vanderbilt investigators report that dysregulation of certain immune cells in the intestines may lead to inflammation and disease. Read More

The Vanderbilt Diabetes Research and Training Center (VDRTC) is celebrating its 44th year of operation with a five-year competitive renewal of its $9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). Read More

This week Douglas Heimburger, M.D., M.S., professor of Medicine at Vanderbilt, joined a growing chorus calling for preservation of the Fogarty International Center of the National Institutes of Health (NIH). Read More

Vanderbilt investigators have developed a new method for measuring oxidative stress in human tumors, which provides insight into cancer development. Read More

RSV infection reduces the risk of infection with human rhinovirus, which could have implications for vaccine development and prevention strategies for viral respiratory tract infections in infants. Read More

Interventions that increase circulating levels of compounds called EETs may improve insulin sensitivity and treat hypertension. Read More

Two brain signaling pathways have overlapping functions in regulating anxiety, suggesting that therapeutics aimed at one or the other will impact both. Read More